All In Biotech

Drug Trial Radar · NCT06350630

Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study

Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA)Nephropathy Course QUIgAN Study

Last checked: Nov 20, 2026Latest source record: Oct 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 334 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

334

Planned (sponsor's estimate)

Start

Jun 26, 2025

Primary completion

Dec 31, 2027

Study completion Dec 31, 2030

Sponsor

Lead sponsor
Centre Hospitalier Universitaire de Saint EtienneAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Ministry of Health, France
First posted
Apr 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

immunoglobulin A (IgA) nephropathy (Berger disease) is the most frequent primary glomerulonephritis worldwide. This disease accounts for about 5% of the causes of end stage renal disease in France, representing a major public health issue. Its pathophysiology seems to be triggered by mucosal immunity abnormalities leading to the systemic misaddressing of mucosal IgA, generation of circulating immunoglobulin A1 (IgA1) immune complexes finally deposited in renal glomeruli leading to renal tissue inflammation and scarring processes. Among this pathogeny, innate immunity is involved at several steps, including mucosal immunity. In this regard, hydroxychloroquine has been shown to generate a global anti-inflammatory effect, particularly through its action on Toll like receptors and dendritic cells. This drug is well tolerated, widely used for other auto-immune diseases (e.g. Systemic Lupus Erythematosus) and very low priced. One randomized controlled study conducted in China has recently shown a significant drop in proteinuria of IgA nephropathy patients treated with hydroxychloroquine (-48.4%) compared to the placebo group (+10.0%), after a quite short-term follow-up (6 months) and a moderate statistical power (30 patients in each group). Considering (i) the potential mechanism of therapeutic effect on this disease, (ii) the well documented safety profile of the drug for rheumatologic indications and posologies, and its low cost (iii) its efficacy in reducing proteinuria in IgA nephropathy patients in a preliminary Chinese randomized control study, the investigators aim in this study at establishing the beneficial impact of hydroxychloroquine on IgA nephropathy in a double blind randomized controlled trial on a Caucasian French population with harder outcomes and a longer follow-up compared to the Chinese preliminary study.

Conditions

  • IgA Nephropathy

Interventions

  • Hydroxychloroquine Oral TabletDrug

    Active hydroxychloroquine once daily by oral route at 6.5 mg/kg of ideal weight/day, with maximal dose of 400mg/day for 3 years

  • Placebo oral tabletDrug

    placebo once daily by oral route (no active drug - same dosage as hydroxychloroquine )

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Absolute difference in estimate Glomerular Filtration Rate (GFR) between hydroxychloroquine group and control group evolutionTime frame: 3 years

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • CHU Gabriel Montpied

    Clermont-Ferrand, France · Recruiting

  • Hospices Civils de Lyon

    Lyon, France · Recruiting

  • AP-HM Hôpital de la Conception

    Marseille, France · Recruiting

  • Chr Metz Thionville Hopital Mercy

    Metz, France · Recruiting

  • APHP Hôpital Bichat

    Paris, France · Recruiting

  • APHP Hôpital de Tenon

    Paris, France · Recruiting

  • CHU Lyon Sud

    Pierre-Bénite, France · Recruiting

  • CHU de Saint-Etienne

    Saint-Etienne, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.